Trial Profile
A Phase I, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD0466 in Patients With Advanced Hematologic or Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 Aug 2023
Price :
$35
*
At a glance
- Drugs AZD-0466 (Primary)
- Indications Acute myeloid leukaemia; Adrenal cancer; Anal cancer; Bladder cancer; Cholangiocarcinoma; Colorectal cancer; Haematological malignancies; Lung cancer; Lymphoma; Multiple myeloma; Myelodysplastic syndromes; Pancreatic cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Sarcoma; Small cell lung cancer; Solid tumours; Tumour lysis syndrome; Urogenital cancer
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
- 20 Apr 2023 According to Starpharma media release, clinical trial data from this trial presented in a poster presentation by AstraZeneca at the AACR Annual Meeting.
- 22 Mar 2023 According to Starpharma media release, company will present the new data of this study at the upcoming American Association for Cancer Research Annual Meeting in April 2023.
- 22 Apr 2022 Status changed from completed to discontinued.